Literature DB >> 8029636

Prolonged in vivo IL-4 treatment inhibits antigen-specific IgG1 and IgE formation.

R van Ommen1, A E Vredendaal, H F Savelkoul.   

Abstract

IL-4 is obligatory for primary IgE responses, whereas primary IgG1 and secondary IgE responses are partially IL-4 independent. To investigate the effect of IL-4 on the antigen-specific memory formation for these isotypes, BALB/c mice were treated after primary TNP-KLH immunization with recombinant IL-4 for a period fo 4 months. This prolonged presence of a high IL-4 level resulted in increased serum levels of total IgG1 and IgE, whereas total IgG2a did not change. The expression of CD23, but not I-Ad, increased on the splenic B cells. IL-4 treatment did not affect the IL-4 production by Con A stimulated spleen cells, whereas it did decrease the IFN-gamma production. In the same mice the TNP-specific IgG1 and IgE serum levels, however, were decreased. Similar results were found when the antigen was continuously present during the IL-4 treatment. Furthermore, it was shown that IL-4 decreased the formation of IgG1 and IgE memory cells. These results point to different effects of IL-4 in regulating antigen-specific and bystander responses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8029636     DOI: 10.1111/j.1365-3083.1994.tb03425.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  3 in total

Review 1.  Cytokines as adjuvants for vaccines: antigen-specific responses differ from polyclonal responses.

Authors:  C E Taylor
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

2.  Correction of the X-linked immunodeficiency phenotype by transgenic expression of human Bruton tyrosine kinase under the control of the class II major histocompatibility complex Ea locus control region.

Authors:  D Drabek; S Raguz; T P De Wit; G M Dingjan; H F Savelkoul; F Grosveld; R W Hendriks
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

3.  Immunotherapy with monoclonal antibodies directed against the immunosuppressive domain of p15E inhibits tumour growth.

Authors:  M S Lang; E Hovenkamp; H F Savelkoul; P Knegt; W Van Ewijk
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.